Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Hemogenyx (HEMO)

Price 362.50p on 29-01-2025 at 17:30:02
Change 5.00p 1.4%
Buy 369.00p
Sell 356.00p
Buy / Sell HEMO Shares
Last Trade: Buy 114.00 at 363.80p
Day's Volume: 1,207
Last Close: 362.50p
Open: 357.50p
ISIN: GB00BQVXM815
Day's Range 0.00p - 0.00p
52wk Range: 0.876p - 420.00p
Market Capitalisation: £13m
VWAP: 361.80451p
Shares in Issue: 4m

Recent Trades History Hemogenyx (HEMO)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 114 363.80p Ordinary
15:53:25 - 29-Jan-25
Sell* 4 356.65p Ordinary
15:12:19 - 29-Jan-25
Buy* 130 363.80p Ordinary
14:58:16 - 29-Jan-25
Buy* 539 362.00p Ordinary
11:52:59 - 29-Jan-25
Sell* 1 355.00p SI Trade
11:39:15 - 29-Jan-25
Buy* 184 362.00p Ordinary
11:38:56 - 29-Jan-25
Buy* 1 368.10p Ordinary
10:36:10 - 29-Jan-25
Sell* 50 352.6848p Ordinary
10:08:12 - 29-Jan-25
Sell* 1 351.90p Ordinary
10:06:07 - 29-Jan-25
Unknown* 2 369.00p OTC Trade
08:04:18 - 29-Jan-25

Share Price History for Hemogenyx

Time period:
to
Date Open High Low Close Volume

Share News for Hemogenyx

IN BRIEF: Hemogenyx Pharmaceuticals raises GBP340,000 for drug trial

8th Jan 2025 11:49

Hemogenyx Pharmaceuticals PLC - London-based biotechnology company - Says it has raised GBP340,000 through the placing of 100,000 shares at 340p each. The financing will be dedicated to the clinical trial of its HG-CT-1 drug, which is used for treatment of acute myeloid leukaemia in adults. The first patient for the trial has been recruited and is being tested to ensure they satisfy the clinic protocol. Read More

Hemogenyx opens first clinical site for leukaemia therapy trial

30th Dec 2024 12:01

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Monday reported the opening of the first clinical site in its HG-CT-1 phase 1 trial. Read More

TRADING UPDATES: SDX plots AIM exit; Celadon receives funds

6th Dec 2024 15:40

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More

UK shareholder meetings calendar - next 7 days

2nd Dec 2024 13:32

Read More

IN BRIEF: Hemogenyx to launch myeloid leukemia treatment phase 1 trial

30th Oct 2024 11:09

Hemogenyx Pharmaceuticals PLC - London-based biopharmaceutical company focused on treatments for blood diseases - Schedules the opening of the first clinical site for the phase 1 clinical trial of Hemo-Car-T, a treatment for relapsed or refractory acute myeloid leukemia in adults, formally called HG-CT-1, for the third week of November. The site will open following clearance from the Institutional Review Board and a site initiation visit. Read More

FTSE 100 Latest
Value8,557.81
Change23.94

Login to your account

Forgot Password?

Not Registered